Lexicon Pharmaceuticals Inc（LXRX）の株式分析LXRXLexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is engaged in research and development of drug candidates and the commercialization of the drug, INPEFA (sotagliflozin). INPEFA reduces the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease (CKD), and other cardiovascular risk factors. Sotagliflozin is an orally delivered small molecule drug candidate as a treatment for hypertrophic cardiomyopathy (HCM) and conducts the SONATA-HCM pivotal Phase 3 clinical trial of sotagliflozin in that indication. The Company develops pilavapadin, an orally delivered small molecule drug candidate, as a treatment for neuropathic pain. The Company also develops LX9851, an orally delivered small molecule drug candidate, for the treatment of obesity and associated cardiometabolic disorders. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Lexicon Pharmaceuticals Inc is not a good buy right now due to its current price of $1.42 being significantly lower than the analyst price target of $8, indicating potential upside. However, the RSI is at a very low 18.814, suggesting the stock is oversold. The recent 5-day change is down 6.58%, and the stock has a high level of risk due to its small-cap status and recent negative performance. Investors should be cautious as the company has reported significant net losses, with a net income of -31775000 USD in Q2 2026, and a forward P/E ratio of 0, indicating uncertainty about future profitability.

7 analysts cover LXRX: 4 rate it Buy, 3 Hold and 0 Sell. The average price target is 4.03.